STUDY QUESTION: Is the genome-wide response of human cumulus cells to FSH and insulin-like growth factors (IGFs) comparable to the response observed in undifferentiated granulosa cells (GCs)?
Introduction
Infertility affects over 10% of reproductive-aged women, 40% of whom suffer from ovulatory dysfunction (Li and Ng, 2012) . Ovulation is the culmination of the folliculogenesis process that takes up to a year to complete in humans. Normal folliculogenesis requires interplay between endocrine and locally produced factors. Unequivocally, the most crucial endocrine factor is FSH, while the insulin-like growth factor (IGF) system is one of the most important local factors. The block in preovulatory follicle formation observed in both FSH/FSH receptor and IGF1 full knockout mice underscores the importance of these hormones during normal follicular development (Baker et al., 1996; Kumar et al., 1997; Dierich et al., 1998) . Therefore, understanding the interaction between FSH and the IGF system may lead to advances in infertility treatments by exploiting the mechanisms that coordinate these signals.
We have shown that FSH actions in granulosa cells (GCs) are enhanced by IGF1 in rodents and by IGF2 in humans and depend on IGF1 receptor (IGF1R) signaling in both species (Zhou et al., 2013; Baumgarten et al., 2014 Baumgarten et al., , 2015 . In IVF patients, the diminished response to FSH observed in the presence of low IGF levels in the follicular fluid (Bahceci et al., 2007) and the need for fewer FSH doses for those with high IGF concentrations (Oosterhuis et al., 1998) suggest strong FSH and IGF interactions during follicle development. This evidence opens the possibility of pharmacological interventions of the IGF1R pathway to manipulate FSH actions. However, the integrated genomic response of human GCs to FSH and IGFs has not been determined. Understanding the mechanisms involved in the regulation of GC differentiation will contribute much needed knowledge to improve the efficiency and safety of infertility treatments and fertility preservation. In this report, we characterize a novel experimental approach to study GC differentiation using cumulus cells from IVF patients and provide a genome-wide overview of the response of human cumulus cells to FSH in the presence or absence of IGF1R activity.
Materials and Methods

Patients and human cumulus cell culture
We collected cumulus cells from egg donors or women undergoing IVF due to male infertility at the University of Illinois at Chicago Fertility Center under Institute Review Board approval and with patients' consent. Cumulus cells were manually dissected from the oocytes and transported immediately to the laboratory where they were dispersed by gentle pipetting and centrifuged at 500g for 5 min. For each patient, 200 000 cells/well were plated in 12-well plates coated with Matrigel (DB Biosciences, USA) in 0.5 ml of serum-free DMEM-F/12-0.25% w/v bovine serum albumin (BSA) media containing antibiotics. Three hours later, cells were treated for 48 h with or without 50 ng/ml of human recombinant FSH (Serono, USA) in the presence or absence of 0.5 µM of NVP-AEW541 (AEW, Cayman Chemical, USA), an IGF1R inhibitor. The concentrations of FSH and AEW used were based on dose-response experiments (Zhou et al., 2013; Baumgarten et al., 2015) . Microarray determinations were performed using cells from three patients (Table 1) , without pooling cells from multiple patients. To confirm microarray results, cumulus cells from additional patients were used to performed qPCR (n = 6), western blot (n = 3) and reporter assays (n = 5). Estradiol and progesterone concentrations in the media were determined in cells used for PCR and western blot (n = 9).
Microarrays
Total RNA was isolated using Direct-zol (Zymo Research, USA) and hybridized to Affymetrix arrays by the UIC Core Genomics Facility. Signal was normalized to housekeeping genes and to the intensities of hybridization controls. We considered only probes with intensity higher than 50. Significantly regulated genes were determined using Significance Analysis of Microarrays (false discovery rate: 0.01 and confidence level: 90%) and hierarchical clustering of samples was performed using BRB ArrayTools (http:// brb.nci.nih.gov/BRB-ArrayTools/ [10 January 2017, date last accessed]).
Genes showing significant differential expression between groups (P < 0.01) were classified into functional groups using BRB ArrayTools and GeneCoDisc3 (Nogales-Cadenas et al., 2009) .
Quantitative PCR
Total RNA (1 µg) was reverse transcribed using anchored oligo-dT primers (IDT, USA) and MMLV reverse transcriptase (Invitrogen, USA) at 42°C for 1 h. The resulting cDNA was diluted to a final concentration of 10 ng/µl. Primer sequences are available upon request. Target gene expression was adjusted to the expression of ribosomal L19 mRNA (Rpl19).
Estradiol and progesterone measurements
Cell culture medium was diluted 1:300 (estradiol) or 1:30 (progesterone) and used for steroid determinations by ELISA (DRG Instruments, USA) following manufacturer's instructions.
Promoter reporter assays
The CYP19 320 -Luc reporter was generated by cloning the +1 to −320 region of the human CYP19 ovarian promoter followed by the firefly luciferase cDNA into pTRIP (Stove et al., 2006) . Lentivirus containing this construct were generated as previously described (Zhou et al., 2013) . Empty plasmids were used as controls. Cells were infected with lentivirus and after overnight incubation treated as described above for 48 h. Luciferase activity was determined in 50 μl of lysates as previously described (Zhou et al., 2013) .
Western blot
Antibodies against CYP19A1 (Epitomics, USA), HIF1A, CYR61, GADD45A and DDIT4 (Cell Signaling, USA) were used to assess protein expression by western blot as previously described (Baumgarten et al., 2014) .
Statistical analysis
Graphed data represent the mean value ± SEM. For qPCR, western blot and ELISA statistical comparisons were performed using one-way analysis of variance followed by Tukey test. Differences between groups were considered to be statistically significant at P < 0.05.
Results
Global differential gene expression
To uncover transcriptional changes induced by FSH and determine the contribution IGF1R activity, we performed microarray analyses on cells treated with FSH in the presence or absence of the selective IGF1R inhibitor, NVP-AEW541 (AEW). Unsupervised hierarchical clustering indicated a good separation between control, FSH, AEW and FSH + AEW treated groups (Fig. 1) . This suggests that cumulus cells respond strongly to FSH and that IGF1R inhibition significantly hinders FSH effects. Differentially expressed genes were determined in control versus FSH and control versus AEW groups. Also, because human GCs produce IGF2 (Baumgarten et al., 2015) , FSH and AEW groups were compared to account for the effect of endogenous IGF2 on gene expression.
When compared with controls, FSH significantly (≥1.5-fold) increased the expression of 601 transcripts, whereas it inhibited 527 mRNAs. Treatment with AEW alone had minor effects; only 12 genes were stimulated, and 56 genes were inhibited. In contrast, 1600 transcripts were differentially regulated when the FSH and AEW groups were compared, of which 950 genes were increased, and 650 were decreased. Scatter plots illustrate these effects (Fig. 1) . The full list of genes can be accessed at GEO number GSE86427.
To determine the contribution of IGF1R activity on the regulation of human GCs by FSH, we listed FSH-regulated genes for which the cotreatment with AEW minimally or significantly affected FSH actions (Supplementary Tables SI and SII Table SII) .
Biological functions enriched in FSH and IGF1R activated cells
Gene ontology (GO) analyses revealed the enrichment of transcripts involved in steroid biosynthesis, steroid metabolism, cholesterol biosynthesis, proliferation and hormone synthesis. In addition, processes including extracellular matrix reorganization, cellular movement, survival and apoptosis were overrepresented (Supplementary Table SIII) . Interestingly, the 'cellular response to FSH pathway' was also significantly enriched, adding support to the use of cumulus cells to study FSH-induced differentiation.
Cholesterol and steroid synthesis
Microarray analysis showed strong enrichment of transcripts involved in cholesterol metabolism and steroid synthesis ( Fig. 2A) . The function and regulation of these mRNAs are illustrated in Figure 2B . The steady-state level of mRNAs involved in cholesterol and steroid synthesis was validated in six additional patients using qPCR. In agreement with the microarray results, StAR, CYP11a1, HSD3b2, HSD11b, CYP19a1 and INSIG1 were stimulated by FSH (Fig. 2C ). While the regulation of CYP11a1, HSD3b2 and INSIG1 by FSH was not affected by AEW co-treatment, the stimulation of CYP19a1, StAR and HSD11b1 by FSH was significantly reduced. These results agree with the inhibition of FSH-induced estradiol production by the cotreatment with AEW (Fig. 2D) . Interestingly, progesterone production was not affected by FSH or by AEW. Western blot analysis confirmed that FSH stimulates aromatase expression in cumulus cells, and that AEW inhibits FSH-induced aromatase expression (Fig. 2E) .
The microarray results also revealed that cumulus cells express GATA4 and NR5A2/LRH1, and that FSH stimulates LRH1 and GATA4 expression (Fig. 2A) . The effect of FSH on LRH1 was confirmed by qPCR (Fig. 2C) .
Finally, we studied the effect of FSH on CYP19 promoter activity. The activity of this promoter was low in untreated cells, but FSH stimulated its activity by 20-fold (Fig. 2F) . Co-treatment with AEW decreased the stimulatory effect of FSH by~50%. Treatment with AEW alone had no effect on promoter activity.
Genes involved in GC differentiation
FSH up-regulated factors that participate in follicle growth, including IGF2, LHCGR, AREG, FOXL2, HIF1A, Inhibin A, NPR3 and VEGFA but inhibited SFRP4, TNFRSF11B and CTGF (Supplementary  Table SII) . PCR confirmed these results and demonstrated that AEW co-treatment prevents IGF2, HIF1a and FOXL2 expression. In contrast, the effect of FSH on LHCGR, AREG, SFRP4, CTGF, INHA and VEGFA was not affected by AEW (Fig. 3) . Western blot confirmed the expression and regulation of HIF1A (Fig. 3) .
Extracellular matrix and cytoskeleton enriched transcripts
FSH stimulated the expression of extracellular matrix (ECM) proteins including collagen IV alpha 1 and 2 and inhibited the expression of versican (Supplementary Table SIV) . AEW prevented FSH stimulation of collagens but not the inhibition of versican. In addition, FSH increased by 4-fold the expression of glypican 6, which belongs to the family of proteoglycans implicated in the control of cell growth and division. FSH also inhibited the expression of components of the cytoskeleton, including tubulin (2-fold), actinin alpha 1 (5-fold), calponin (2-fold), transgelin (11-fold) and CNN1 (13-fold). Co-treatment with AEW partially prevented transgelin and CNN1 inhibition. The effect of FSH on TAGLN expression was confirmed by PCR (Fig. 4) .
Proliferation
FSH increased cyclin E and cyclin-dependent kinase 1 (CDK1) and decreased cyclin-dependent kinase inhibitor 2B (CDKN2B). Stimulation of CDK20 and SCAPER (S-phase cyclin A-associated protein in the ER) was also observed in cells treated with FSH. Moreover, FSH decreased GADD45a, an inhibitor of proliferation (Perugini et al., 2009) , and increased DDIT4, which stimulates proliferation and reduces apoptosis (Chang et al., 2009) . These data are the first illustration of GADD45a and DDIT4 regulation in ovarian GCs. PCR confirmed expression and regulation of GADD45a and DDIT4 in human cumulus cells (Fig. 4A ).
In addition, we demonstrate the expression of GADD45a and DDIT4 proteins in human GCs. Thus, GADD45a protein was consistently decreased by FSH while the DDIT4 protein was stimulated (Fig. 4B) .
FSH also had profound effects on genes not associated previously with ovarian function. For example, FSH stimulated TGFBR3, NPTX2 and TSPAN12 and decreased CYR61, ANKRD1, TAGLN and disheveled binding antagonist of β-catenin 1 (DACT1) levels. AEW cotreatment did not significantly alter the regulation of these genes by FSH. PCR data confirmed these microarray findings (Fig. 4A ) and western blot confirmed the inhibition of CYR61 by FSH, an effect that was not prevented by AEW (Fig. 4B ).
Transcription regulators of GC differentiation
Differentially expressed genes were used to predict upstream regulators. Twenty-seven transcription factors were significantly enriched including SP1, AP2A, P53, STAT1, ESR1, HIF1A and SMAD4 (Supplementary  Table SV ). SP1 was predicted to target 93 differentially regulated transcripts including SCARB1, StAR, CYP11a1, CYP19a1 and LHCGR, which participate in cholesterol and steroid synthesis and DDIT4, a novel target of FSH in GCs. This analysis suggests that SP1 may play a crucial role in the regulation of GC differentiation in humans. Remarkably, we observed no enrichment of genes with cAMP response element binding (CREB) protein response elements.
Discussion
The scarcity of preantral follicles hampers mechanistic studies of GC differentiation in humans and in the rare situations where human follicles are obtained, these follicles are undergoing atresia (Yuan and Giudice, 1997) . Therefore, it is difficult to get healthy undifferentiated human GCs regularly. We have demonstrated that cumulus cells express significantly lower levels of differentiation markers than mural cells (Baumgarten et al., 2014) . Here, we used human cumulus cells from IVF patients to study the effects of FSH and IGFs on global gene expression. The results clearly indicate that the response of cumulus cells mimics that of preantral GCs undergoing FSH-induced differentiation (Lindeberg et al., 2007) .
Steroidogenesis
A hallmark of GC differentiation in all species studied thus far is the induction of aromatase (CYP19a1), which is exclusively under the control of FSH (Danilovich et al., 2000) . Here, we show that in human cumulus cells FSH robustly stimulates the activity of the ovarian promoter of the CYP19a1 gene and increases the mRNA and protein levels of aromatase. In addition, these results confirm our previous publications showing that FSH and IGF1R activity are required for the maximal induction of aromatase and estradiol production (Zhou et al., 2013; Baumgarten et al., 2014 Baumgarten et al., , 2015 . Our findings also show that FSH induces the expression of StAR and CYP11a1 in cumulus cells. Similar effects of FSH have been observed in human preantral GCs but not in mural GCs from IVF patients (Lindeberg et al., 2007) . Finally, cumulus responded to FSH with an increase in GATA4 and NR5A2/LRH1, which are transcription factors involved in the stimulation of steroidogenic enzymes. We and others have shown that FSH increases GATA4 and LRH1 in rat GCs isolated from preantral follicles (Falender et al., 2003; Kwintkiewicz et al., 2007; Pelusi et al., 2008) . Together, these findings support the idea that the steroidogenic response of cumulus cells to FSH resembles that of undifferentiated GCs.
Treatment with high doses of FSH can lead to luteinization, but this only occurs in long-term (6 days) cultures (Kreeger et al., 2005) . In addition, the process of luteinization is accompanied by a decrease in aromatase expression (Hickey et al., 1990) . In our study, cumulus cells were treated with FSH for only 2 days and responded with an increase in aromatase; therefore, it is unlikely they luteinized. Moreover, cumulus cells produce more estradiol in the presence of FSH. These cells do not, however, respond to FSH with a rise in progesterone, despite the stimulation of StAR, CYP11a1 and HSD3B. Although striking, this finding further demonstrates that cumulus cells do not luteinize after 48 h treatment with FSH. While previous reports show that FSH increases progesterone production in rodent undifferentiated GCs (Saxena et al., 2007; Chowdhury et al., 2016) and human GCs from early antral follicle (Lindeberg et al., 2007; Hardy et al., 2016) , these studies used serum to promote cell attachment, a practice we do not follow. It is possible that coating plates with serum provides additional factors necessary for progesterone production. Indeed, GCs will spontaneously luteinize in serum-supplemented cultures (Murphy, 2000) . Further studies are required to elucidate the effect of FSH on progesterone secretion in cumulus cells.
FSH also increases HSD11b1, which converts cortisone into cortisol, an effect that was reduced 50% by AEW suggesting that FSH and IGFs cooperatively stimulate cortisol production in follicles. Of note, HSD11b1 stimulation by FSH was observed in rat GCs from preantral follicles (Escamilla-Hernandez et al., 2008) .
Cholesterol synthesis
GCs require cholesterol for membrane biogenesis, cell signaling and steroid synthesis. Here, we demonstrate that FSH increases the expression Figure 3 Quantitative PCR confirmation of ovarian-related genes.
Cumulus GCs were cultured in serum-free media as described for microarray experiments. Messenger RNA levels were analyzed by qPCR and data normalized to Rpl19. Blots are representative of three patients. Columns with different letters differ significantly; six patients were used for each group. of lipoprotein receptors and the expression of ACAT2, HMGCS1, HMGCR, SC5D and DHCR7, which are involved in cholesterol synthesis (Hu et al., 2010) . Thus, FSH stimulates the uptake and de novo synthesis of cholesterol. These transcripts were also found to be stimulated by FSH in undifferentiated rat GCs . Similarly, the expression of SREBF1, a transcription factor that controls cholesterol synthesis, was increased by FSH in human cumulus cells, consistent with previous findings in undifferentiated rat GCs . We also observed that FSH stimulates insulin-induced proteins (INSIG1), a protein that participates in the activation of SREBF1. Finally, FSH stimulated LDLR, SCARB1, VLDLR and several of their associated proteins including LRP11 and HILPDA. FSH increases SCARB1 and LDLR production in murine GCs isolated from immature preantral and antral follicles (Azhar et al., 1998; Lai et al., 2013) . Taken together, these results suggest that human cumulus cells respond to FSH by increasing de novo cholesterol synthesis and producing more lipoprotein receptors. Importantly, these FSH-induced effects have been previously described in undifferentiated GCs of several species, providing strong support for the use of cumulus cells as an experimental approach to study FSH-regulated mechanisms during GC differentiation in humans. Moreover, these results provide new information demonstrating that the IGF system interacts closely with FSH to increase cholesterol content and estradiol secretion in human GCs.
Follicle growth
Treatment of human cumulus cells with FSH led to the regulation of genes involved in the preantral to preovulatory transition. For instance, we observed a 12-fold increase in INHA subunit and a 2.9-fold decrease of INHBB subunit in cumulus cells treated with FSH. The balance between activins and inhibins shifts throughout follicle development, with primary to preantral follicles mainly expressing β subunits to form activins, and larger preovulatory follicles expressing more α Selected differentially regulated genes involved in ovarian function. For reference purposes, the average signal for Control (C), AEW (A) and FSH (F) groups is shown. The fold changes between F versus C (F/C) and F versus A (F/A) are listed in bold. P: t-test value for each comparison.
subunit, to form inhibin A or B. This shift is controlled by FSH (Knight et al., 2012) . The abundance of INHBB and the low levels of INHA found in untreated cumulus cells (Table 2 ) support the idea that these cells resemble more a preantral than a preovulatory phenotype. Moreover, it has been speculated that TGFBR3 (or beta glycan) antagonizes activin in GCs of the preovulatory follicle. Thus, FSH stimulation of TGFBR3 agrees with the decline in INHBB and the increase in INHA observed in cumulus cells treated with FSH. FSH also stimulates TGFBR3 in rat GCs from preantral follicles (Omori et al., 2005) . Interestingly, FSH is able to regulate INHBB and INHA even in the presence of the IGF1R inhibitor. These findings demonstrate for the first time that FSH plays a major role in the regulation of the inhibin/ activin system in human GCs without the intervention of the IGF1R. Luteinizing hormone receptor (LHCGR) induction is also a marker of GC differentiation (Peng et al., 1991) . We demonstrated that human cumulus cells express significantly lower levels of LHCGR compared with mural cells but retain CYP19a1 and FSHR expression (Baumgarten et al., 2014) . Here, we extend these observations and show that FSH increases LHCGR in cumulus cells in culture. In contrast to aromatase, inhibition of IGF1R receptor activity had no effect on LHCGR stimulation. Therefore, the mechanism by which FSH regulates aromatase and LHCGR differ significantly.
CTGF is mainly expressed in GCs and is involved in the regulation of follicular development and ovulation (Nagashima et al., 2011) . In rat GCs, CTGF mRNA levels are down-regulated by FSH; hence, CTGF mRNA and protein reach their lowest levels in large antral follicles and are highly expressed in undifferentiated GCs (Wandji et al., 2000; Slee et al., 2001) . Our data indicate that CTGF is highly expressed in human cumulus cells and is strongly inhibited by FSH.
SFRP4 acts as a soluble antagonist of Wnt signaling. In rodents, SFRP4 expression is up-regulated in GCs of large antral follicles after treatment with hCG and remains highly expressed in the corpus luteum (Hsieh et al., 2003) . We found however that FSH strongly antagonizes SFRP4 expression. The role of SFRP4 in the human ovary is unknown; we propose that FSH prevents early luteinization of GCs by inhibiting SFRP4. Interestingly, we observed that FSH also decreases the expression of DACT1. These results suggest, therefore, that FSH indirectly stimulates the WNT pathway.
Hyaluronan synthase 2 (Has2) and pentraxin 3 (PTX3) are stimulated in cumulus cells after the LH surge and are involved in cumulus cell expansion (Sugiura et al., 2010) . In our study, FSH decreased Has2 and PTX3, suggesting that it may delay cumulus expansion until the LH surge takes place.
Proliferation by novel FSH targets
Our data revealed that CYR61 and ANKRD1 are highly expressed in human cumulus cells and that their expression is inhibited by FSH. CYR61 suppresses cell growth (Tong et al., 2004) , whereas ANKRD1 inhibits proliferation by acting as a cofactor for p53 to upregulate p21, an inhibitor of the cell cycle (Kojic et al., 2010) . Thus, FSH inhibition of CYR61 and ANKRD1 may contribute to promoting proliferation. In addition, GADD45A inhibits cell growth and survival (Perugini et al., 2009 ) but DDIT4 promotes cell proliferation and reduced apoptosis (Chang et al., 2009) . We show that FSH decreases GADD45a and induces DDIT4 expression at the mRNA and protein level in human cumulus cells. These changes along with the increase in CDK1 and inhibition of CDKN2B could be key steps in FSH stimulation of proliferation we described previously (Baumgarten et al., 2015) .
SP1 role in human GC differentiation
The analysis of transcription factor binding sites associated with differentially regulated genes revealed that SCARB1, StAR, CTGF, HIF1A, CYP11a1, CYP19a1 and LHCGR all contain SP1 binding sites in their promoters, suggesting an important role for SP1 in human cumulus cells. It is striking, however, that this analysis found no enrichment of genes regulated by CREB. Conceivably, SP1, but not CREB, may play a major role in the activation of FSH targeted genes. In fact, CREBdeficient mice are fertile (Hummler et al., 1994) , suggesting that it is not required for normal GC function. Further research is necessary to determine the role of SP1 in the overall response of GCs to FSH.
Conclusions
This report delineates, for the first time, the effect of FSH on the transcriptome of human cumulus GCs and shows that the response of these cells to FSH closely mimics that of undifferentiated preantral GCs isolated from laboratory animals. Additionally, it describes the expression and regulation of several genes not previously identified in human GCs. In support of our findings, a recent report suggested that cumulus cells do not luteinize after hCG treatment (Egbert et al., 2016) . It is possible that cumulus cells avoid luteinization due to their low expression of LHCGR (Amsterdam et al., 1975; Bortolussi et al., 1977) . Thus, we propose the use of cumulus cells as a representative and valid experimental approach to advance our understanding of human GC differentiation and, ultimately, folliculogenesis.
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